Key result
The Physicians' Health Study randomized 22,000 male U.S. physicians to aspirin and/or beta carotene for the primary prevention of cardiovascular disease and cancer.
Why the study?
Does aspirin and/or beta carotene prevent cardiovascular disease and cancer in male U.S. physicians aged 40 to 84?
RCT (n=22,000)
Double-blind
Does aspirin and/or beta carotene prevent cardiovascular disease and cancer in male U.S. physicians aged 40 to 84?
Answers are grounded in this paper and cite their sources.
This editorial introduces the preliminary report of the Physicians' Health Study, a large-scale randomized trial evaluating aspirin for the primary prevention of cardiovascular disease.
Under the somewhat ill-defined rubric "Special Report," we publish in this week's issue a preliminary report from the Physicians' Health Study, a double-blinded, controlled trial of aspirin in the prevention of cardiovascular disease and of beta carotene in the prevention of cancer.1 After more than 59,000 volunteers were screened, 22,000 male U.S. physicians 40 to 84 years of age were entered in the trial and randomly assigned to receive one of four treatments: (1) buffered aspirin (325 mg) and beta carotene (50 mg), (2) buffered aspirin and beta carotene placebo, (3) aspirin placebo and beta carotene, and (4) aspirin placebo . . .
No takes yet. Share an insight, caveat, or question.
Arnold S. Relman (1988) conducted an RCT in Primary prevention of myocardial infarction (n=22,000). Aspirin and beta carotene vs. Placebo was evaluated on Cardiovascular disease and cancer. The Physicians' Health Study randomized 22,000 male U.S. physicians to aspirin and/or beta carotene for the primary prevention of cardiovascular disease and cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: